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Abstract: Enterotoxigenic Escherichia coli (ETEC) is a significant source of morbidity 
and mortality worldwide. One major virulence factor released by ETEC is the heat-labile 
enterotoxin LT, which is structurally and functionally similar to cholera toxin. LT consists 
of  five B subunits carrying a single catalytically active A subunit. LTB binds  the 
monosialoganglioside GM1, the toxin’s host receptor, but interactions with A-type blood 
sugars and E. coli lipopolysaccharide have also been identified within the past decade. 
Here, we review the regulation, assembly, and binding properties of the LT B-subunit 
pentamer and discuss the possible roles of its numerous molecular interactions.  
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1. Introduction 
1.1. Enterotoxigenic Escherichia coli 
Enterotoxigenic  Escherichia coli  (ETEC) causes a form of intestinal disease termed traveler’s 
diarrhea, which affects nearly every population worldwide. In general, this malady is self-limiting in a 
healthy adult, although antibiotics are often prescribed [1]. In addition to traveler’s diarrhea, ETEC can 
cause disease  symptoms clinically indistinguishable from cholera caused by Vibrio cholerae [2,3]. 
ETEC is endemic in many developing countries, including Mexico and Bangladesh, and is frequently 
encountered by tourists, members of the military, or other visitors [1]. Because of poor surveillance, 
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mortality due to ETEC is difficult to estimate, but there are believed to be at least 400,000   
ETEC-related deaths in children under the age of 5 each year, with countless others likely classified 
simply as death due to diarrhea [4]. Human ETEC strains are closely related to numerous isolates taken 
from pigs suffering from diarrhea, with both types of ETEC sharing a number of pathogenic features 
and virulence factors, including heat-labile enterotoxin (LT). However, human and porcine ETECs 
show strong host preferences that are understood to be due to the expression of fimbriae with distinct 
tropisms [5]. 
A large of number of disease-causing ETEC strains have been isolated from patients, with over  
70 identified O-antigen serogroups, along with over 25 recognized variants of adhesive fimbriae and a 
pair of enterotoxin families carried by ETEC at varying frequencies (see below) [6]. 
Extrachromosomal plasmids carrying virulence determinants are present in the vast majority of ETEC 
strains, providing the bacteria with the genes to produce toxins and fimbriae as well as the potential to 
mobilize these genes, creating new enterotoxigenic strains [7]. Attempts to generate an effective 
vaccine against ETEC, particularly for young children, have mostly met with failure due to the highly 
variable nature of the antigens present amongst strains [8]. 
1.2. Enterotoxins produced by ETEC 
By convention, ETEC strains are classified based on their expression of LT (described in detail in 
this review), a heat-stable enterotoxin (ST), or both [9]. ST molecules are small peptides that mimic 
the native intestinal hormone guanylin and activate guanylyl cyclase [10], and LT was originally named 
to describe a heat-sensitive enterotoxigenic factor distinguishable from the heat stability of ST. A 
second class of LT molecules, termed LT-II, also exists (the prototypical class of LT is sometimes 
called LT-I). While structurally similar, the B subunit of LT-II shares little sequence similarity to LT-I, 
and strains expressing LT-II are rarely isolated from human patients [11]. Unless otherwise stated, ‘LT’ 
will refer solely to human LT-I in this review. 
Incubation of LT at 70 °C for 10 minutes is sufficient to destroy its activity [12], whereas boiling 
does not inactivate ST. ST and LT both serve to disrupt the balance of electrolytes in the intestine, 
causing the diarrhea associated with ETEC infection. Out of 798 LT isolates surveyed in 1997, 196 
(25%) expressed LT, 376 (46%) expressed ST, and 231 (29%) carried both toxins [9]. Thus, over half 
of all ETEC isolates express LT. The activity of LT promotes the adherence of ETEC cells to 
enterocytes in vitro [13], and expression of LT is required for ETEC to colonize the mouse intestine 
and to cause disease symptoms in gnotobiotic piglets [14,15]. Thus, while all ETEC isolates have the 
potential to cause diarrhea, those expressing LT may have an advantage in terms of colonization. 
In terms of both structure and function, LT is closely related to cholera toxin (CT) from V. cholerae. 
Like CT, LT is a multimeric AB5 toxin, composed of a single A subunit (LTA) associated with a ring 
of five B subunits (LTB) [16]. Figure 1 shows the structure and subunit organization of LT. Heat 
treatment of the toxin breaks down the pentameric LTB ring into monomers, releasing LTA. While 
catalytic activity is present in free LTA, the LTB pentamer is required for entry into cells of the 
intestinal epithelium, and disruption of the holotoxin thereby prevents intoxication of host cells [17].  
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Figure 1. The structure and subunit organization of LT. (A) The crystal structure of LT 
holotoxin, generated using Swiss-PDB viewer (version 4.0.1) using PDB number 1LTA. 
The globular A1 fragment and the helical A2 peptide can be seen in blue, along with a ring 
of five B subunits. (B) A schematic of the subunit organization of LT. (C) A schematic of 
LT showing a cutaway view of the toxin’s central core. The location of the site of 
proteolytic processing (“nicking”), which is subtended by a disulfide bond, is circled. 
Nicking occurs after secretion of the toxin, and the disulfide is reduced inside the host cell, 
releasing the catalytically active A1 fragment. 
 
1.3. Catalytic activity of LT 
Early research efforts determined that the catalytic activity of LT is identical to that of CT, which 
had already been characterized. Specifically, LTA ADP-ribosylates an arginine residue in the α subunit 
of the host Gs  protein [18]. This modification leads to inhibition of the GTPase activity of Gsα, 
rendering adenylate cyclase constitutively active. Increased levels of cyclic AMP (cAMP) in the host 
cell open several channels, including the cystic fibrosis transmembrane receptor, resulting in the loss of 
fluid and electrolytes into the intestinal lumen [19]. cAMP-dependent cellular events also lead to the 
downregulation of antimicrobial peptides in the intestine [20]. LTA displays limited auto-ADP-ribosylation 
activity, especially when overexpressed, but this reaction does not seem to influence its function [21]. 
During activation, LTA is proteolytically cleaved, releasing a helical C-terminal fragment termed 
A2; the remaining A1 polypeptide is responsible for the observed toxic effects. This cleavage event, 
termed “nicking,” is not required for the toxic effects of LT, but mutants that are unable to be nicked 
demonstrate a markedly delayed effect in cell culture, and nicking doubles the toxin’s   
ADP-ribosyltransferase activity in vitro [21]. Trypsin is able to cleave LTA into A1 and A2 in vitro, 
but the identity of the protease(s) involved in this activation step in vivo is not known [22]. In addition 
to this cleavage event, a disulfide bond linking A1 and A2 is also reduced after entry into the host cell 
in order to completely separate the two fragments [23]. This disulfide bond is not essential to holotoxin 
formation, but mutation of the cysteine residues involved makes LTA more sensitive to degradation by 
proteases and generates a significant lag in cAMP production in cultured intestinal cells compared to 
wild-type toxin [24]. 
1.4. Homology to CT 
LT is encoded by a two-gene operon, with the gene for LTA (eltA) overlapping with the start of the 
gene for LTB (eltB) by four nucleotides [25]. These genes have been referred to as etxAB or toxAB in Toxins 2010, 2                         
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some older studies [26] but will be called eltAB here, following recent convention. Given the identical 
subunit structure and catalytic activity, it is perhaps unsurprising that the nucleotide sequences of the 
genes for CT and LT are highly similar. The eltAB operon demonstrates approximately 78% overall 
nucleotide sequence identity to the ctxAB  operon coding for CT [27]. While the DNA sequences 
display a fairly uniform similarity throughout, the amino acid sequences of the subunits of CT and LT 
contain “hotspots” of greater divergence. The most divergent regions include the signal sequences 
targeting the subunits to the periplasm (see below) and the A2 peptide [27]. Most relevant to the ligand 
binding properties described in this review, the two mature B subunits share 83% amino acid 
identity [28].  
Sequence analysis indicates that the genes encoding LT were acquired by horizontal transfer from  
V. cholerae around 130 million years ago, long after V. cholerae and E. coli diverged as species [29]. 
In ETEC, eltAB is found on an extrachromosomal virulence plasmid called pEnt [30]. When surveying 
ETEC strains, these genes were found to be flanked by approximately 250 base pairs of conserved 
sequence, often followed by partial or intact insertion sequence (IS) elements [30]. IS elements similar 
to those flanking eltAB  are frequently observed next to genes encoding host-binding fimbriae, 
suggesting a general mechanism for the transfer of virulence-related genes. In addition, entire pEnt 
plasmids can be transferred to non-pathogenic strains of E. coli, rendering them toxigenic [31]. 
2. Regulation of LT Production 
2.1. Growth conditions inducing the release of LT 
Unlike the extensively studied regulatory network controlling CT production [32], less is known 
about the transcriptional regulation of eltAB. Alteration of ETEC’s growth conditions revealed that a 
pH of 7.5–8.0 maximizes the amount of LT released; moreover, LT is not produced in detectable 
quantities at temperatures lower than 26 °C, with toxin production increasing along with temperature 
and reaching a peak at 37 °C [33,34]. It has also been observed that the addition of glucose to the 
growth media induces the release of LT [33,35]. In addition, oxygen levels and osmolarity were found 
to influence toxin expression. Specifically, microaerophilic conditions and increased salt 
concentrations (>171 mM) both promote the production of LT [36]. In general, conditions that mimic 
those found in the human small intestine, where LT is expected to play a role in ETEC-associated 
pathogenesis, are optimal for production of the toxin.  
The presence of short-chain fatty acids (particularly those with carbon chain lengths between three 
and eight) in the growth media impairs the production of LT [37]. Short-chain fatty acids are produced 
in relatively large quantities in the colon, where they stimulate fluid absorption in a cAMP-independent 
manner [38]. Thus, they may serve to signal ETEC that it has reached the large intestine and no longer 
needs to produce high quantities of LT, having passed its target, the ileum. Additionally, the presence 
of short-chain fatty acids may indicate to ETEC that conditions in the gut favor the absorption of liquid 
by the colonic epithelium and that the production of LT would not be effective.  
While many of these conditions (e.g., higher temperature) consistently induce LT production, it 
should be noted that not all ETEC isolates are identical in the levels of LT that they produce. A study 
of 26 LT-positive Brazilian ETEC isolates found that the secreted levels of the toxin varied almost  Toxins 2010, 2                         
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50-fold [39]. While the amount of LT produced correlated well with fluid accumulation in a rabbit ileal 
loop model, LT-hyperproducing strains were isolated from diarrheic patients and asymptomatic 
patients with equal frequencies in that study. Although there is no way to tell whether the production of 
LT measured in vitro recapitulated the strains’ phenotypes in vivo, a careful study of eltB expression in 
diarrheagenic ETEC isolates both immediately after collection and later, after freezedown and storage, 
indicated little change due to in vitro growth [40]. Therefore, while LT certainly contributes to disease 
symptoms, the regulation of LT production may occur differently in individual ETEC isolates. 
2.2. Regulation by H-NS 
Apart from characterization of the growth conditions favoring LT production, little was known 
about the transcriptional regulation of  eltAB  for decades. The conserved region upstream of eltA 
contains a strong consensus promoter, and the region downstream of eltB  contains a probable 
transcriptional terminator, indicating that these genes are transcribed as a single message [30,41]. In 
1998, Trachman and Maas noted that deletion of the eltA gene elevates the levels of mRNA transcribed 
from the operon’s promoter, which they determined to be due to lack of a downstream regulatory 
element bound by the nucleoid-associated protein H-NS [42]. In a strain lacking H-NS, eltAB is not 
repressed at low temperatures [42]. Later work by another group uncovered two distinct but 
cooperative binding sites for H-NS positioned in the region downstream of the promoter [43]. These 
sites are found at regions of DNA predicted to have significant curvature, a feature of H-NS binding 
elements [43]. While there is interplay between the effects of temperature and osmolarity, the 
regulation of eltAB  in response to salt concentration is independent of H-NS and its regulatory 
element [36]. Therefore, H-NS is responsible for temperature regulation of LT, but it is unclear which 
bacterial factors are able to sense osmotic conditions and short-chain fatty acids. 
2.3. Feedback from cAMP 
Another important regulator of the transcription of eltAB is cAMP, an end product of LT’s catalytic 
activity. As described above, the catalytic activity of LTA causes an increase in cAMP levels in host 
cells. Some of this cAMP is shed into the intestinal lumen after treatment with LT [44], and there is 
evidence that exogenous cAMP can be sensed by ETEC. Namely, conditioned supernatant from ETEC-
treated intestinal epithelial cells (or pure cAMP, the active component) stimulates the   
LT-dependent adherence of ETEC to enterocytes in vitro [13]. It was later determined that bacterial 
cAMP receptor protein (CRP) suppresses the transcription of eltAB  by binding to an operator 
overlapping the σ
70  consensus binding site [45]. While seemingly contradictory, these results may 
define a feedback loop, whereby the production of LT can be downregulated once a certain amount of 
cAMP has been released by the cells of the intestinal epithelium.  
The identification of CRP as a negative regulator of LT synthesis also served to explain earlier 
observations regarding glucose. Glucose inhibits bacterial cAMP production, lowering levels of active 
CRP and thereby upregulating LT production [45]. As glucose is absorbed by the small intestine, 
ETEC is likely to encounter higher concentrations of the sugar in early sections of the gut [46]. Thus, 
early exposure to glucose may induce the production of LT to aid in adherence to the ileum, where 
most ETEC cells are found in a mouse model of colonization [14]. Interestingly, ST production is Toxins 2010, 2                         
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stimulated by CRP [45], suggesting that ETEC may predominantly produce one toxin at a time during 
infection. Together, these results leave us with a model whereby ETEC senses conditions that identify 
the small intestine and, in turn, upregulates the production of LT (Figure 2). Once ETEC has reached 
the large intestine, LT synthesis shuts off as the bacteria prepare to exit the host. 
Figure 2. A model of the regulation of eltAB during infection. (A) In an environmental 
reservoir at ambient temperature, low osmolarity and H-NS act to repress the eltAB 
promoter. No LT is produced. (B) Upon entry into the host intestine, free glucose and 
higher temperature de-repress the eltAB operon by inhibiting cAMP receptor protein (CRP) 
and H-NS, respectively. High levels of LT are produced. High osmolarity may also 
contribute to the production of LT by an unknown mechanism. (C)  ETEC reaches the 
ileum, where it begins to multiply, adhering to intestinal cells due to the activity of LT. In 
the ileum, glucose concentrations are lower due to intestinal absorption, and significant 
amounts of cAMP have been released by host cells in response to LT. These signals 
combine to repress eltAB via CRP. Little new LT is produced. (D) In the large intestine, 
CRP and short-chain fatty acids produced by commensal bacteria fully repress eltAB. The 
mechanism of repression by short-chain fatty acids is unknown. ETEC shuts off the 
production of LT in preparation to exit the host.  
 
3. Holotoxin Assembly 
3.1. Periplasmic localization 
Both LTA and LTB feature signal sequences directing them to the periplasm of E. coli through the 
Sec translocation machinery. For LTA, this signal is 18 amino acids in length, while LTB contains a 
21-amino acid signal peptide [47,48]. Each peptide sequence contains positive charges at the 
beginning, a core of hydrophobic residues, and a tyrosine or histidine residue near the cleavage site, in 
line with typical sec-dependent signals. For many years, the periplasm was thought to be the terminal 
destination of LT [49], although it is now known that it remains periplasmic in laboratory strains of  
E. coli because they do not express a functional type II secretion system (see below). Toxins 2010, 2                         
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Once LTA and LTB subunits reach the periplasm, they spontaneously assemble into holotoxins 
containing one A subunit and five B subunits. Pentamers form quite rapidly; within one minute, 80% 
of newly transported LTB has formed into pentamers, about half of which carry LTA [50]. LTA is 
actually produced in slight excess, such that around 1.5 LTA subunits are found for every 5 LTB 
subunits in the periplasm. Pulse-chase studies of LTA determined that 90% of periplasmic LTA is 
associated with B-subunit pentamers at any one time, but half of newly transported LTA does not form 
holotoxins [50]. Thus, it is likely that LTA is made in excess because it can be easily degraded in the 
periplasm before it can assemble into holotoxins. Fully formed holotoxin is remarkably stable, 
remaining assembled at any pH between 2.0 and 11.0 [51]. Moreover, while exposure to strong acidic 
conditions dissociates the B pentamer, free monomers re-oligomerize upon neutralization with no 
additional factors present [16]. 
3.2. Factors influencing oligomerization 
Much of what is required to form LT holotoxins exists within the amino acid sequences of the 
subunits themselves. To date, the only prokaryotic factor known to be required for the formation of LT 
(and CT) is DsbA, a periplasmic disulfide oxidoreductase. LTB contains a single disulfide bridge 
linking Cys-9 and Cys-86. Disruption of this bond with a reducing agent such as dithiothreitol prevents 
reassembly of LT after dissociation in acid, and a transposon insertion in the V. cholerae homolog of 
dsbA  was reported to abolish the heterologous production of LT [16,52]. LTA also features an 
important disulfide bond linking the A1 and A2 fragments at Cys-187 and Cys-199, the formation of 
which is presumably catalyzed by DsbA. Other studies of the mechanism behind the acid dissociation 
of LT and its subsequent reassembly under neutral conditions showed that isomerization of Pro-93 in 
the B subunit blocks oligomerization [53]. The results of that study suggest that proper formation of 
LT requires the activity of a peptidyl proline isomerase in vivo, but this hypothesis has yet to be tested. 
While free B subunits are intrinsically capable of assembling pentamers, the presence of LTA 
enhances pentamer formation. Consequently, a larger amount of oligomerized LTB can be found when 
LTA is co-expressed [16]. This effect is due to the A2 peptide, as deletion of the last 14 amino acids 
from LTA significantly slows the formation of B-subunit pentamers [54]. Interestingly, the last four 
amino acids of LTA (Arg-Asp-Glu-Leu) may specifically be critical for anchoring LTA in the newly 
formed pentamer. LTA mutants lacking these residues are able to readily induce LTB oligomerization, 
but are not found with the assembled pentamers [54]. Thus, the “cargo” subunit of LT (LTA) also 
lends a hand in the assembly of native toxin. 
B-subunit mutants that are defective in pentamer assembly have also been isolated. LTB in which 
the final amino acid residues, Ser-Met-Glu-Asn, have been replaced with Gly-Leu-Asn oligomerize 
approximately 10 times slower than wild-type LTB [54]. As salt bridges between the A2 peptide and 
the last five amino acids of LTB were identified in the crystal structure of LT [55],  C-terminal 
alterations to LTA and LTB may be expected to disrupt holotoxin synthesis. In vitro studies using a 
monoclonal antibody directed against the first 10 amino acids of LTB have implicated the extreme  
N-terminus of the B subunit in pentamer assembly, as well [51]. Taken together, these reports show 
that LTB is self-sufficient in terms of its folding and assembly, and that LTA stabilizes the holotoxin 
and accelerates pentamer formation. Toxins 2010, 2                         
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4. Secretion 
4.1. Type II secretion 
Studies initially characterizing LT noted that it was found in association with aggregates in the 
culture supernatant that had outer membrane-like characteristics [33,56]. Several studies, in fact, 
described endotoxin activity and/or outer membrane fragments that were associated with LT so tightly 
that it complicated their attempts at purifying the toxin [33,57]. Nevertheless, early studies considered 
the periplasm to be the final destination for LT. However, it was also noted that LT could be secreted 
into the supernatant when heterologously expressed in V. cholerae [58]. Moreover, a mutant V. 
cholerae strain unable to secrete CT was also unable to secrete LT, indicating a common pathway for 
the export of both toxins [58]. Later research determined that the secretion of CT is dependent on a 
pathway called the type II secretion system [59]. Found in numerous gram-negative  species, this 
system consists of a complex of 12–15 proteins spanning the inner and outer membranes [60]. 
In 2002, Tauschek and colleagues identified an operon in H10407 ETEC (gspC-M) coding for a 
functional type II system [61]. This system is required for the secretion of LT, debunking the apparent 
paradox of an extracellular pathogen producing a toxin that remains inside its own cell. Further 
implicating the type II system in mediating the release of LT, expression of the E. coli K-12 type II 
operon is necessary and sufficient for the export of LT from MC4100 E. coli cells [62]. The genes 
encoding the type II apparatus are also regulated by H-NS [63,64], indicating that they would be turned 
on under the same conditions that favor the production of LT.  Furthermore, the type II system in 
ETEC is capable of secreting CT [65], consistent with results from the expression of LT in   
V. cholerae.  
Secretion of LT is based on the B-subunit pentamer; LTA is not a secretion-competent 
substrate [66]. Given the high similarity between CTB and LTB, one could expect similar mutations to 
impair the native secretion of each toxin. Indeed, one such mutation (E11K) that reduces the secretion 
efficiency of LT and CT has been found [65,67]. However, the identification of several other mutations 
affecting the secretion of one toxin but not the other indicates that LT and CT are recognized in 
different ways by their respective secretion machineries [65]. Moreover, two CTB mutants that are 
impaired for secretion in V. cholerae are secreted with wild-type efficiency from ETEC. Because these 
toxins are interchangeable as secretion substrates, future studies using secretion-deficient mutants 
could identify the portion(s) of the type II secretion apparatus that are involved in substrate recognition. 
Other studies determined that the secretion of LT from ETEC strain H10407 was dependent on the 
activity of a protein called LeoA, which was later characterized as a GTPase [68,69]. As only 3% of 
strains tested in a study of numerous ETEC isolates carried the leoA gene [70], and ΔleoA mutants 
demonstrate pleiotropic effects [68], the role of LeoA in the secretion of LT is certainly not a universal 
one. ATPase activity is required for type II secretion, and it is possible that H10407 uses LeoA to 
provide additional energy for the export of LT.  
4.2. Secretion via outer membrane vesicles 
The existence of extracellular LT was also explored in a second series of studies. Two reports 
characterized the secretion of active LT in association with outer membrane vesicles (OMVs) released Toxins 2010, 2                         
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by ETEC [71,72]. OMVs are spherical structures approximately 50–200 nm in diameter, composed of 
protein and lipid, that are released from all gram-negative bacteria studied to date [73] (A.J. Kulp and 
M.J. Kuehn, Annu. Rev. Microbiol., in press). As the name suggests, OMVs are derived from the outer 
membrane, but periplasmic components are also present within their lumens. In recent years, OMVs 
have been shown to play a role in the virulence associated with a number of pathogens [74]. In the case 
of ETEC, active LT is found both inside OMVs and associated with their surface [71]. The basis and 
implications of this association will be discussed below. 
5. Ganglioside Binding 
5.1. LT’s interaction with GM1 
Three decades ago, the host receptor for CT was determined to be the monosialoganglioside GM1 
(Galβ3GalNAcβ4(NeuAcα3)Glcβ1-ceramide), with LT later shown to bind the same receptor [75]. 
When the crystal structures of CTB and LTB bound to GM1  pentasaccharide or galactose were 
compared, it was noted that the residues contacting the terminal galactose sugar in GM1 are conserved 
between the two toxins [76], explaining their similar affinities for the host receptor. The binding 
pocket for GM1 is located at the interface of two adjacent subunits, with Gly-33 providing the sole 
contribution of the second LTB monomer. Only B-subunit pentamers, and not monomeric CTB or 
LTB, are able to bind GM1 [77,78]. With five B subunits, there are five GM1 binding sites available in 
LTB. Whereas CTB has been modeled with five GM1 molecules bound [79], only one or two wild-type 
GM1 binding sites are required for internalization and toxicity of CT, albeit with slower kinetics [80]. It 
is not yet clear whether the same is true for LT. 
The terminal galactose residue of GM1 forms the most contacts with LTB and CTB, whereas only 
slight interactions with the sialic acid residue of the ganglioside have been observed [79]. The 
significant contact between LTB and the terminal galactose sugar, 79% of which is buried within the 
binding pocket, likely explains the strong preference for binding GM1 over other gangliosides (see 
Section 5.2). The LTB residues involved in GM1 binding are indicated in Figure 3.  
Consistent with the model presented in Figure 2, the rabbit ileum is enriched in GM1 compared to 
other sections of the small intestine [81]. Binding to GM1 that is located in lipid rafts on host intestinal 
cells is critical for the canonical pathway leading to LT’s toxic effects through increased cAMP levels. 
As such, the binding pocket has become an attractive target for chemical inhibitors, and several   
studies have involved screening galactose-based small-molecule libraries for possible receptor 
antagonists [82,83]. After GM1 binding, LT is internalized and undergoes retrograde transport to the 
endoplasmic reticulum [23]. There, LTA is able to retrotranslocate into the cytosol to reach its target, 
Gsα. While an increasing number of studies are focused on the events surrounding LT after it enters the 
host cell, host effects and intracellular trafficking are not the focus of this review. Indeed, the 
intracellular transport of CT has been reviewed elsewhere in this special issue [84]. Ganglioside 
binding has also been shown to be important for the adjuvant properties ascribed to LTB and CTB. 
Excellent reviews of the use of CT-like enterotoxins as adjuvants are available elsewhere [85], so this 
property will not be discussed here either. Toxins 2010, 2                         
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Figure 3. The mature polypeptide sequence of LTB, with residues involved in binding to 
GM1  (green circles), blood sugars (red circles), and lipopolysaccharide (blue circles) 
indicated. Lighter shades of circles indicate residues coordinating solvent molecules only. 
Amino acids involved in binding to GM1 (specifically, the terminal galactose moiety) and 
A-group blood sugars were identified by crystallization studies [28,76]; residues involved 
in lipopolysaccharide binding are inferred based on the binding phenotypes caused by 
mutating specific amino acids [65,86]. Asterisks indicate Tyr-18 and Thr-47; classical CTB 
contains a His at position 18, and El Tor CTB variants contain an Ile at position 47. These 
substitutions are thought to explain the lack of blood sugar binding by CTB [28]. Ala-46 
(boxed) is mutated to Glu in porcine LTB, likely explaining its lack of binding to blood 
sugars [87]. Numbering of the LTB sequence starts with the first residue in the mature 
protein, after cleavage of the sec-dependent signal sequence.  
 
5.2. Additional non-GM1 substrates 
The structural requirements of CT’s receptor binding seem rather strict; GM1 is the only ganglioside 
that CTB binds to with any substantial affinity [88]. Due to the existence of several hydrogen bonds 
contacting the terminal galactose of GM1, substitution of another sugar in this position is not tolerated 
by CTB or LTB [76]. However, a number of studies have shown that LTB can bind with low affinities 
to additional gangliosides, including one lacking a sialic acid residue (asialo-GM1), one with a second 
sialic acid residue (GD1b), and others containing a terminal N-acetyllactosamine disaccharide   
(e.g., paragloboside) [88,89] (Table 1). The structural basis of this difference in binding is not entirely 
clear. There is some disagreement in the literature about the ability of LTB to bind GM2, which lacks 
the terminal galactose residue present in GM1, and the ability of CTB to bind GD1b [75,88–90]  
(Table 1). LT binding to GM2 was found using gangliosides immobilized on microtiter plates and thin 
layer chromatography assays [89,90]. Using GM2-containing liposomes as substrates for surface 
plasmon resonance, no LT binding was seen [88]. Given the extensive binding of the terminal 
galactose sugar in the crystal structures of CT and LT [76,79], it is difficult to imagine GM2 binding 
being important in vivo. Another study showed that linoleic acid, an unsaturated fatty acid found in Toxins 2010, 2                         
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bile, could competitively inhibit GM1 binding by LT [91]. However, the exact nature of this binding 
event is unknown, and the authors concluded that normal amounts of bile would not provide sufficient 
linoleic acid to impair LT’s toxicity in vivo. 
Table 1. Summary of the structures of the gangliosides bound by CTB and LTB and the 
relative binding affinities of those interactions.  ++++, strong binding; +, some weak 
binding; -, no binding; +/-, conflicting reports of weak binding and no binding (see text for 
references). Gal = galactose, GalNAc = N-acetylgalactosamine, Sia = sialic acid   
(N-acetylneuraminic acid), Glc = glucose, GlcNAc = N-acetylglucosamine,  
Cer = ceramide.  
Ganglioside  Structure  LTB binding  CTB binding 
GM1 
 
++++  ++++ 
Asialo-GM1    +  - 
Paragloboside    +  - 
GD1b 
 
+  +/- 
GM2 
 
+/-  +/- 
The physiological role of binding to non-GM1  gangliosides is currently undefined, although 
paragloboside can act as active receptor for LT in the rabbit intestine [89]. Paragloboside binding is 
largely restricted to LTB from porcine isolates, which contains three amino acid substitutions 
compared to human LTB (S4T, A46E, and E102K) [87]. However, human ETEC isolates sometimes 
carry a version of LTB identical in amino acid sequence to porcine LTB [92], and therefore, the 
relevance of this binding to human infection should not be completely dismissed. Binding to 
alternative gangliosides is of much lower affinity than LTB-GM1 binding (with KD values 10–25 times 
higher than that of GM1 binding), so it is easiest to imagine transient binding to non-GM1 gangliosides. 
That is, they may represent suboptimal substrates that allow LT to remain proximal to the surface of a 
host cell until it encounters GM1 and becomes internalized.  
6. Blood Sugar Binding 
6.1. LTB binds to A-type blood sugars 
For many years, researchers noticed that there were many more receptors for LT on the surface of 
the intestinal mucosa than receptors for CT and that a significant population of these receptors could 
not be bound by CT, indicating that they were not GM1 [81]. While the presence of additional 
ganglioside substrates for LT is certain to contribute to these observations, an increasing pool of Toxins 2010, 2                         
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evidence pointed toward blood antigens providing these extra binding sites. First, LT was observed to 
bind best to the brush borders of pigs with type A blood (with no blood type-dependent binding 
observed for CT) [93] and to human erythrocytes with A or B glycolipids [94]. These results were 
confirmed using rabbit intestinal membranes, for which the ABH blood determinants were actually 
functional receptors, leading to GM1-independent fluid accumulation [95]. Later, blood group A 
glycoconjugates on cultured human intestinal cells were shown to provide functional additional 
receptors for soluble LT [96,97].  
6.2. Residues of LTB involved in blood sugar binding 
In 2007, LTB was co-crystallized in association with type-2 A group blood antigen pentasaccharide 
(GalNAcα3(Fucα2)Galβ4(Fucα3)Glcβ) [28]. Higher-affinity blood sugar binding had originally been 
observed for an artificially created LTB/CTB hybrid molecule [98], but the crystal structure 
demonstrated that wild-type LTB also binds blood antigen sugars. Blood antigen binding is based on a 
peripheral binding pocket, distinct from the residues involved in GM1 binding [28] (Figures 3 and 4). A 
series of residues at positions 44–47 provides the majority of the observed protein-sugar contacts, 
along with Gln-3 from an adjacent subunit [28]. Consistent with the crystal structure, several point 
mutations involving critical residues in LTB (Q3K, Y18A, A46D, and T47A) abolish binding to the A 
group terminal trisaccharide, as determined by ELISA [86]. Porcine LTB contains a Glu residue at 
position 46 in place of the Ala residue in human LTB (see Figure 3). Because the A46D mutation in 
LTB abolishes blood sugar binding [86], it is likely that the A46E substitution explains the lack of 
porcine LTB binding to A-type glycolipids [87].  
Figure  4.  Peripheral sugar-binding pockets on LTB. (A) A rendering of the molecular 
surface of LT, with residues involved in blood sugar binding colored red, residues 
implicated in LPS binding colored blue, and residues involved in both binding events 
colored magenta. These residues lie on the interface between two B subunits, colored white 
and green. For reference, the galactose moiety of GM1 is colored and circled in black in (A) 
and depicted with a black star in (B).  The image was rendered in Swiss-PDB viewer 
(version 4.0.1) using PDB number 1LTA. (B) A schematic representation of the subunit 
structure rendered in (A). 
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Binding to B-type blood sugars, which feature a terminal galactose in place of the   
N-acetylgalactosamine found in A sugars, is supported by LTB [94], but evidence from a study using 
the LTB/CTB hybrid indicates that binding to a closely related type-1 A blood antigen is not 
possible [99]. The type-1 A antigen only differs from the type-2 molecule that can be bound by LT in 
the nature of the linkage between two terminal sugars, so it would seem that perturbing the orientation 
of the sugar molecules in the blood antigen even slightly can disrupt this low-affinity binding event. 
While the blood sugar-binding site is physically distinct from the GM1 binding site, several of its 
residues are directly adjacent to residues involved in GM1 binding (see Figure 3). One study reported 
that incubation of LTB with the terminal trisaccharide from A-type blood antigen does not inhibit GM1 
binding [86]. However, another study showed that GM1 oligosaccharide could inhibit LTB binding to 
the larger A9 type-2 glycolipid substrate [100]. Given the proximity of the residues involved in each 
binding event, it is possible that both binding events do not (and cannot) occur at one LTB-LTB 
interface, but binding to GM1 and blood sugars may be able to occur at different locations within the  
B-subunit pentamer. 
6.3. ETEC infection and blood type 
The severity of V. cholerae infection is linked to blood type. Specifically, patients with O blood type 
are more likely to develop severe symptoms than their counterparts with A, B, or AB blood type [101]. 
In contrast, the effect of blood type on ETEC infection is much less clear [102], but a recent cohort 
study of ETEC-based diarrhea in Bangladesh found an increased prevalence of the disease among 
children with A or AB blood type [103]. Complicating the search for a correlation between ETEC 
infection and blood type is the existence of the so-called “secretor” phenotype. ABH blood type 
determinants are found in large quantities on intestinal cells, but some patients also release these 
glycoconjugates in their intestinal mucosal secretions [104,105]. Thus, extracellular A-type sugars may 
serve as decoys for LT binding in individuals with the secretor phenotype, thus protecting them against 
the toxin. In contrast, non-secretor patients of A blood type may in fact have additional functional 
receptors for the toxin. Future studies in which patients with ETEC-based diarrhea are screened for 
both the secretor phenotype and blood type will provide information regarding the possible use of 
blood group sugars as receptors in vivo. 
7. Lipopolysaccharide Binding 
7.1. Binding of LT to the E. coli surface is due to an association with lipopolysaccharide 
In addition to its ability to bind host gangliosides and blood sugars, further research has shown that 
LT binds to lipopolysaccharide (LPS) on the surface of E. coli cells [62]. LPS is the predominant 
component of the outer membrane of gram-negative bacteria, consisting of a characteristic lipid 
moiety, Lipid A, linked to a series of sugar residues [106]. This oligosaccharide chain can be further 
divided into an inner core of 5–6 sugars, an outer core of 4–5 additional sugars, and the O antigen, an 
oligosaccharide motif repeated up to 50 times. Figure 5 shows the structure of E. coli LPS. 
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Figure  5.  The structure of E. coli  LPS.  LPS consists of a characteristic lipid moiety   
(Lipid A) anchored in the outer leaflet of the outer membrane, followed by a series of sugar 
residues making up the inner and outer cores. In wild, non-laboratory strains (including 
ETEC), further oligosaccharide repeats known as the O antigen are present. Experimental 
evidence indicates that LT binding is mediated primarily through contacts with the outer 
core, with binding to Kdo possible if LPS is truncated (see below). In this diagram, the core 
structure of K-12 E. coli (such as DH5α) is presented.  
 
The discovery of LT binding to LPS explains a number of prior observations, including the surface-
bound population of toxin molecules detected on ETEC OMVs [71]. Further experiments 
demonstrated that exogenously added LT can bind the surface of LT-deficient strains of ETEC [62,86]. 
This surface association is not dependent on the presence of the A subunit and is slightly enhanced by 
prior protease treatment [62]. These results indicate that the binding substrate for LTB is not likely to 
be a protein and that degradation of outer membrane proteins may in fact reveal more toxin   
binding sites. 
A series of preincubation experiments determined that soluble LPS significantly inhibits the binding 
of LT to the surface of an LT-deficient ETEC strain [62]. Moreover, LPS lacking O antigen was 
equally effective as full-length LPS, if not more so, suggesting that the core sugars of LPS were the 
target of LT binding (Figure 5). Preincubation with Lipid A, the lipid portion of LPS, or several other 
bacterial phospholipids had no effect on the surface binding of LT. A later study reported that the 
presence of the innermost LPS sugar, 3-deoxy-D-manno-octulosonic acid (Kdo), is the minimal 
requirement for LT binding, but that a full oligosaccharide core is preferred [107].  
Interestingly, while CT is able to bind to the surface of ETEC cells, neither LT nor CT binds to the 
surface of Vibrio cells [107]. Along the same lines, E. coli LPS inhibits the binding of CT and LT to 
the ETEC surface, but Vibrio LPS does not inhibit the ETEC surface binding of LT [107]. Thus, 
differences in the LPS structures of these two species of bacteria are likely to be responsible for the 
observed binding phenotypes. Among several differences, Kdo residues are phosphorylated in Vibrio, 
and the expression of a Kdo kinase in E. coli inhibits the surface binding of LTB [107]. Toxins 2010, 2                         
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Beyond its composition, the presentation of LPS seems to be critical for binding by LT. It has been 
noted that LT does not bind to LPS adsorbed to microtiter plates [100]. However, LT binds readily to 
the surface of E. coli cells [62,86] and to LPS reconstituted into liposomes (D.L. Rodriguez and M.J. 
Kuehn, unpublished data). Therefore, it seems that proper orientation of the LPS molecules (and, 
perhaps, the presence of multiple, side-by-side LPS molecules) is important for LT binding. As LT has 
a relative low affinity for blood sugars compared to GM1 [99], it is distinctly possible that the LT-LPS 
interaction, which involves several of the same residues (see Section 7.2), is also of low affinity. LPS 
adsorbed to the bottom of a microtiter well may not present its sugar residues freely enough to allow 
for significant LT binding. Differences in LT binding to the ganglioside GM2 have also been noted 
based on whether the substrate was present in liposomes or directly adsorbed to microtiter plates   
(see Section 5.2). 
7.2. LTB residues involved in LPS binding 
Several experiments indicated that LPS binding is due to residues outside the GM1-binding pocket. 
GM1 does not inhibit the binding of LT to the surface of bacteria, and LPS does not inhibit LT’s  
GM1-dependent toxicity in cell culture [62]. Moreover, LT is able to mediate the internalization of 
OMVs from a non-toxic strain of E. coli into cultured enterocytes in a GM1-dependent manner [108].  
Upon identification of the binding pocket responsible for the association between LTB and blood 
group sugars, several key coordinating residues were mutated and confirmed to be required for blood 
group binding [28,86] (see Figure 3 and Section 6.2). Given the location of the blood group on the 
periphery of the LTB pentamer, distinct from the GM1 binding site, these mutants were also tested for 
binding to the surface of E. coli cells. Indeed, several mutations that affect blood sugar binding also 
reduce LPS binding [86] (Figures 3 and 4). One mutant, T47A, demonstrates a particularly strong 
effect on surface binding to K-12 E. coli and H10407 ETEC cells. However, the residues involved in 
LPS binding are not identical to those involved in blood sugar binding (Figures 3 and 4). For instance, 
mutation of Glu-11, a residue just outside the blood sugar binding pocket, abolishes LPS binding but 
not blood sugar binding [65]. Consistent with the overlapping functions of these peripheral sugar 
binding pockets, preincubation of LT with blood group A trisaccharide blocks subsequent binding to 
the surface of E. coli cells [86]. 
The T47A mutant demonstrates near wild-type levels of binding to Kdo, despite its strong 
impairment in binding to LPS with a full core or ETEC LPS containing an O antigen [86]. 
Furthermore, LTB carrying an E11A mutation does not bind to cells expressing only Kdo, but can bind 
to the full K-12 core present on DH5α (our unpublished data). Therefore, it seems that the sugar(s) 
bound by LT in the context of full-core LPS is/are something other than Kdo, while Kdo binding is 
possible when the sugar becomes available due to LPS truncation. Residues in the peripheral sugar-
binding pocket (including those that no longer bind LPS when mutated) make extensive contacts with 
glucose and substituted galactose residues in A-type blood sugars [28]. As glucose and galactose are 
present in all known E. coli LPS cores [109], but not those of Vibrio [110], it is tempting to speculate 
that they may represent the binding substrate(s) of LTB. 
It has been noted that classical CTB can also bind to E. coli LPS [107], indicating that the binding 
pocket is likely conserved between the two toxins. Indeed, CTB shares the residues implicated in LPS Toxins 2010, 2                         
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binding by LTB (see Figure 3). However, El Tor CTB contains a substitution at Thr-47 (marked with 
an asterisk in Figure 3), replacing the original residue with an Ile residue. This change is remarkably 
similar to the T47A mutation that effectively abolishes LPS binding [86], and therefore, El Tor CTB 
may not bind E. coli LPS. However, the binding of El Tor CTB to LPS has yet to be assessed. 
7.3. Possible roles of LPS binding 
There are a number of possible functions for the LPS binding exhibited by LT. Modulation of toxin 
level is one obvious result of the LT-LPS interaction. In comparison to freely secreted CT, more LT 
remains associated with the bacteria producing it. Conceivably, this interaction reduces the number of 
individual toxin molecules that could enter different host cells. However, the association of LT with 
LPS generates OMVs laden with LT molecules, inside and out. As LT can mediate the internalization 
of entire vesicles (and LT within OMVs contributes to toxicity) [108], these toxin-rich “bombs” may 
intoxicate host cells much more readily through a single binding event. Moreover, the association 
between LT and LPS is robust [71]; association of LT with OMVs may protect the toxin from 
proteolysis. The association with ETEC LPS may also prevent soluble LT from futile binding to 
commensal E. coli cells. 
Another possible role for the LT-LPS interaction is in altering the host response to LT, LPS, or 
both. LT can lead to the intracellular trafficking of OMVs, which may modulate the host response to 
vesicle components. OMV-associated LT has been shown to intoxicate  host cells [108], and it is 
becoming clear that the activation of downstream host response pathways by ETEC OMVs is not 
identical to the response generated by soluble LT (H.J. Chutkan and M.J. Kuehn, unpublished data). 
Further research on the host response to soluble and OMV-bound LT will shed light on the functional 
utility of LPS binding. Lastly, LT may serve as an adhesin molecule, linking ETEC cells to host GM1. 
However, given the importance of LT’s catalytic activity in promoting ETEC adherence to 
enterocytes [13], a function for LT as an adhesin seems less likely. Research using ETEC expressing 
T47A mutant toxin (which demonstrates very little surface binding) will provide additional insight into 
the role of the LT-LPS interaction. 
8. Conclusions 
The B subunit of heat-labile enterotoxin presents astonishing economy of amino acid use. A total of 
103 amino acids make up mature LTB, with a number of them buried in its two α-helices and handful 
of β-strands [111]. With the residues that remain surface exposed, LTB binds the A2 helical peptide 
tail from LTA and forms a pentameric ring, contacting one additional B subunit on each side. In 
addition to a pocket for GM1 binding, two overlapping peripheral sugar-binding pockets enable LTB to 
interact with blood sugars and LPS. LTB also likely makes contacts with one or more components of 
the type II secretion system to be recognized for export from ETEC. Given the wide variety of binding 
events, it is not surprising that a single point mutation in LTB has the potential to disrupt multiple 
processes (e.g., T47A, which disrupts LPS and blood sugar binding, or E11K, which impairs toxin 
secretion and LPS binding) [65,86].  
Recent research has highlighted a few key differences between CT and LT during infection. For 
one, LT’s association with LPS generates a situation in which a majority of secreted LT is found in the Toxins 2010, 2                         
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form of toxic ETEC OMVs (Figure 6). In contrast, CT’s inability to bind Vibrio cells leads to the 
secretion of soluble CT. Moreover, the toxic effects of LT may not be GM1-specific, given the 
likelihood that blood group glycolipids of A (and possibly B) type serve as functional receptors for the 
toxin in vitro and in vivo. To date, the relevance of blood sugar binding has not been characterized  
in vivo. Specifically, it has not been shown that blood sugars act as a viable alternative receptor 
alongside GM1  during ETEC infection, and it is unclear whether LT is trafficked differently after 
internalization via blood sugar receptors.  
Figure 6.  LT and CT binding in the intestine of a host with A blood type. (A)  In a   
non-secretor host, LT is secreted largely in association with ETEC OMVs (both within the 
OMVs and on their surface). Soluble and OMV-associated LT molecules bind to GM1 (left 
cell). After internalization of an intact OMV or LT molecule, fluid and electrolyte loss 
occurs due to the toxin’s enzymatic activity. Because blood antigens are not present in 
intestinal secretions, A-group blood sugars likely also serve as functional receptors for 
soluble LT (right cell). Blood sugars may also be able to allow for the internalization of 
OMVs with surface-bound LT (indicated with question marks). It is not known whether 
soluble and OMV-associated LT traffic through different pathways or whether the route of 
trafficking depends on the nature of the receptor (GM1 vs. blood sugar). (B) In a host with 
the secretor phenotype, A-group blood sugars in intestinal secretions may serve as decoy 
binding substrates, limiting fluid and electrolyte loss due to LT. (C) CT is freely secreted 
by  V. cholerae  and binds only to GM1 on host intestinal epithelial cells, causing toxic 
effects after internalization.  
     
 
Research on blood sugar binding by LT in cell culture or in vivo has exclusively used soluble toxin, 
although a large portion of secreted LT is associated with LPS on the surface of OMVs. As the LPS 
and blood sugar binding pockets overlap significantly (see Figure 3), one cannot assume that soluble 
LT and OMV-bound LT will behave identically in vivo with regard to blood sugar binding. Due to the Toxins 2010, 2                         
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presence of five binding pockets per holotoxin, LPS binding and blood sugar binding may occur 
simultaneously in the context of OMV-bound LT, but this possibility has not yet been investigated. 
Therefore, studies of the association between blood type and ETEC disease must consider the possible 
complications of LPS binding. Furthermore, comparisons of soluble LT and OMV-associated LT may 
need to account for the role of blood sugar binding in the context of actual infection. Since the last 
comprehensive review of LT’s structure and function [17], a number of studies have provided us with 
new information about its regulation, secretion, and binding properties. However, there is much still to 
be learned about this remarkable virulence factor. 
Acknowledgements 
M.J.K. is funded by an Investigator in Pathogenesis of Infectious Disease Award from the 
Burroughs Wellcome Fund and by grants from the National Institutes of Health (R01AI064464 and 
R01AI079068).  
References 
1.  Coster, T.S.; Wolf, M.K.; Hall, E.R.; Cassels, F.J.; Taylor, D.N.; Liu, C.T.; Trespalacios, F.C.; 
DeLorimier, A.; Angleberger, D.R.; McQueen, C.E. Immune response, ciprofloxacin activity, and 
gender differences after human experimental challenge by two strains of enterotoxigenic 
Escherichia coli. Infect. Immun. 2007, 75, 252–259. 
2.  Vicente, A.C.; Teixeira, L.F.; Iniguez-Rojas, L.; Luna, M.G.; Silva, L.; Andrade, J.R.; Guth, B.E. 
Outbreaks of cholera-like diarrhoea caused by enterotoxigenic Escherichia coli in the Brazilian 
Amazon Rainforest. Trans. R. Soc. Trop. Med. Hyg. 2005, 99, 669–674. 
3.  Sack, R.B.; Gorbach, S.L.; Banwell, J.G.; Jacobs, B.; Chatterjee, B.D.; Mitra, R.C. 
Enterotoxigenic Escherichia coli isolated from patients with severe cholera-like disease. J. Infect. 
Dis. 1971, 123, 378–385. 
4.  Qadri, F.; Svennerholm, A.M.; Faruque, A.S.; Sack, R.B. Enterotoxigenic Escherichia coli in 
developing countries: epidemiology, microbiology, clinical features, treatment, and prevention. 
Clin. Microbiol. Rev. 2005, 18, 465–483. 
5.  Fleckenstein, J.M.; Hardwidge, P.R.; Munson, G.P.; Rasko, D.A.; Sommerfelt, H.; Steinsland, H. 
Molecular Mechanisms of Enterotoxigenic Escherichia coli Infection. Microbes Infect. 2010, 12, 
89–98. 
6.  Sanchez, J.; Holmgren, J. Virulence factors, pathogenesis and vaccine protection in cholera and 
ETEC diarrhea. Curr. Opin. Immunol. 2005, 17, 388–398. 
7.  Johnson, T.J.; Nolan, L.K. Pathogenomics of the virulence plasmids of Escherichia coli. 
Microbiol. Mol. Biol. Rev. 2009, 73, 750–774. 
8.  Svennerholm, A.M.; Tobias, J. Vaccines against enterotoxigenic Escherichia coli. Expert Rev. 
Vaccines 2008, 7, 795–804. 
9.  Wolf, M.K. Occurrence, distribution, and associations of O and H serogroups, colonization factor 
antigens, and toxins of enterotoxigenic Escherichia coli. Clin. Microbiol. Rev. 1997, 10, 569–
584. Toxins 2010, 2                         
 
 
1463 
10.  Hughes, J.M.; Murad, F.; Chang, B.; Guerrant, R.L. Role of cyclic GMP in the action of heat-
stable enterotoxin of Escherichia coli. Nature 1978, 271, 755–756. 
11.  Connell, T.D.; Holmes, R.K. Characterization of hybrid toxins produced in Escherichia coli by 
assembly of A and B polypeptides from type I and type II heat-labile enterotoxins. Infect. Immun. 
1992, 60, 1653–1661. 
12.  Gill, D.M.; Clements, J.D.; Robertson, D.C.; Finkelstein, R.A. Subunit number and arrangement 
in Escherichia coli heat-labile enterotoxin. Infect. Immun. 1981, 33, 677–682. 
13.  Johnson, A.M.; Kaushik, R.S.; Francis, D.H.; Fleckenstein, J.M.; Hardwidge, P.R. Heat-labile 
enterotoxin promotes Escherichia coli adherence to intestinal epithelial cells. J. Bacteriol. 2009, 
191, 178–186. 
14.  Allen, K.P.; Randolph, M.M.; Fleckenstein, J.M. Importance of heat-labile enterotoxin in 
colonization of the adult mouse small intestine by human enterotoxigenic Escherichia coli 
strains. Infect. Immun. 2006, 74, 869–875. 
15.  Berberov, E.M.; Zhou, Y.; Francis, D.H.; Scott, M.A.; Kachman, S.D.; Moxley, R.A. Relative 
importance of heat-labile enterotoxin in the causation of severe diarrheal disease in the 
gnotobiotic piglet model by a strain of enterotoxigenic Escherichia coli that produces multiple 
enterotoxins. Infect. Immun. 2004, 72, 3914–3924. 
16.  Hardy, S.J.; Holmgren, J.; Johansson, S.; Sanchez, J.; Hirst, T.R. Coordinated assembly of 
multisubunit proteins: oligomerization of bacterial enterotoxins in vivo and in vitro. Proc. Natl. 
Acad. Sci. USA 1988, 85, 7109–7113. 
17.  Spangler, B.D. Structure and function of cholera toxin and the related Escherichia coli heat-labile 
enterotoxin. Microbiol. Rev. 1992, 56, 622–647. 
18.  Moss, J.; Richardson, S.H. Activation of adenylate cyclase by heat-labile  Escherichia coli 
enterotoxin. Evidence for ADP-ribosyltransferase activity similar to that of choleragen. J. Clin. 
Invest. 1978, 62, 281–285. 
19.  Sears, C.L.; Kaper, J.B. Enteric bacterial toxins: mechanisms of action and linkage to intestinal 
secretion. Microbiol. Rev. 1996, 60, 167–215. 
20.  Chakraborty, K.; Ghosh, S.; Koley, H.; Mukhopadhyay, A.K.; Ramamurthy, T.; Saha, D.R.; 
Mukhopadhyay, D.; Roychowdhury, S.; Hamabata, T.; Takeda, Y.; Das, S. Bacterial exotoxins 
downregulate cathelicidin (hCAP-18/LL-37) and human beta-defensin 1 (HBD-1) expression in 
the intestinal epithelial cells. Cell. Microbiol. 2008, 10, 2520–2537. 
21.  Grant, C.C.; Messer, R.J.; Cieplak, W., Jr. Role of trypsin-like cleavage at arginine 192 in the 
enzymatic and cytotonic activities of Escherichia coli  heat-labile enterotoxin. Infect. Immun. 
1994, 62, 4270–4278. 
22.  Clements, J.D.; Finkelstein, R.A. Isolation and characterization of homogeneous heat-labile 
enterotoxins with high specific activity from Escherichia coli cultures. Infect. Immun. 1979, 24, 
760–769. 
23.  Lencer, W.I.; Hirst, T.R.; Holmes, R.K. Membrane traffic and the cellular uptake of cholera 
toxin. Biochim. Biophys. Acta 1999, 1450, 177–190. Toxins 2010, 2                         
 
 
1464 
24.  Okamoto, K.; Nomura, T.; Fujii, Y.; Yamanaka, H. Contribution of the disulfide bond of the A 
subunit to the action of Escherichia coli  heat-labile enterotoxin. J. Bacteriol.  1998,  180,  
1368–1374. 
25.  Yamamoto, T.; Tamura, T.; Yokota, T.; Takano, T. Overlapping genes in the heat-labile 
enterotoxin operon originating from Escherichia coli human strain. Mol. Gen. Genet. 1982, 188, 
356–359. 
26.  Sandkvist, M.; Hirst, T.R.; Bagdasarian, M. Alterations at the carboxyl terminus change 
assembly and secretion properties of the B subunit of Escherichia coli heat-labile enterotoxin. J. 
Bacteriol. 1987, 169, 4570–4576. 
27.  Yamamoto, T.; Nakazawa, T.; Miyata, T.; Kaji, A.; Yokota, T. Evolution and structure of two 
ADP-ribosylation enterotoxins, Escherichia coli heat-labile toxin and cholera toxin. FEBS Lett. 
1984, 169, 241–246. 
28.  Holmner, A.; Askarieh, G.; Okvist, M.; Krengel, U. Blood group antigen recognition by 
Escherichia coli heat-labile enterotoxin. J. Mol. Biol. 2007, 371, 754–764. 
29.  Yamamoto, T.; Gojobori, T.; Yokota, T. Evolutionary origin of pathogenic determinants in 
enterotoxigenic Escherichia coli and Vibrio cholerae O1. J. Bacteriol. 1987, 169, 1352–1357. 
30.  Schlor, S.; Riedl, S.; Blass, J.; Reidl, J. Genetic rearrangements of the regions adjacent to genes 
encoding heat-labile enterotoxins (eltAB) of enterotoxigenic Escherichia coli  strains.  Appl. 
Environ. Microbiol. 2000, 66, 352–358. 
31.  Scotland, S.M.; Day, N.P.; Rowe, B. Acquisition and maintenance of enterotoxin plasmids in 
wild-type strains of Escherichia coli. J. Gen. Microbiol. 1983, 129, 3111–3120. 
32.  Krukonis, E.S.; Yu, R.R.; Dirita, V.J. The Vibrio cholerae ToxR/TcpP/ToxT virulence cascade: 
distinct roles for two membrane-localized transcriptional activators on a single promoter. Mol. 
Microbiol. 2000, 38, 67–84. 
33.  Kunkel, S.L.; Robertson, D.C. Factors affecting release of heat-labile enterotoxin by 
enterotoxigenic Escherichia coli. Infect. Immun. 1979, 23, 652–659. 
34.  Mundell, D.H.; Anselmo, C.R.; Wishnow, R.M. Factors influencing heat-labile Escherichia coli 
enterotoxin activity. Infect. Immun. 1976, 14, 383–388. 
35.  Gibert, I.; Barbe, J. Cyclic AMP stimulates transcription of the structural gene of the outer-
membrane protein OmpA of Escherichia coli. FEMS Microbiol. Lett. 1990, 56, 307–311. 
36.  Trachman, J.D.; Yasmin, M. Thermo-osmoregulation of heat-labile enterotoxin expression by 
Escherichia coli. Curr. Microbiol. 2004, 49, 353–360. 
37.  Takashi, K.; Fujita, I.; Kobari, K. Effects of short chain fatty acids on the production of heat-
labile enterotoxin from enterotoxigenic Escherichia coli. Jpn. J. Pharmacol. 1989, 50, 495–498. 
38.  Binder, H.J. Role of colonic short-chain fatty acid transport in diarrhea. Annu. Rev. Physiol. 
2010, 72, 297–313. 
39.  Lasaro, M.A.; Rodrigues, J.F.; Mathias-Santos, C.; Guth, B.E.; Regua-Mangia, A.; Piantino 
Ferreira, A.J.; Takagi, M.; Cabrera-Crespo, J.; Sbrogio-Almeida, M.E.; de Souza Ferreira, L.C. 
Production and release of heat-labile toxin by wild-type human-derived enterotoxigenic 
Escherichia coli. FEMS Immunol. Med. Microbiol. 2006, 48, 123–131. Toxins 2010, 2                         
 
 
1465 
40.  Sjoling, A.; Qadri, F.; Nicklasson, M.; Begum, Y.A.; Wiklund, G.; Svennerholm, A.M. In vivo 
expression of the heat stable (estA) and heat labile (eltB) toxin genes of enterotoxigenic 
Escherichia coli (ETEC). Microbes Infect. 2006, 8, 2797–2802. 
41.  Dallas, W.S.; Falkow, S. Amino acid sequence homology between cholera toxin and Escherichia 
coli heat-labile toxin. Nature 1980, 288, 499–501. 
42.  Trachman, J.D.; Maas, W.K. Temperature regulation of heat-labile enterotoxin (LT) synthesis in 
Escherichia coli is mediated by an interaction of H-NS protein with the LT A-subunit DNA. J. 
Bacteriol. 1998, 180, 3715–3718. 
43.  Yang, J.; Tauschek, M.; Strugnell, R.; Robins-Browne, R.M. The H-NS protein represses 
transcription of the eltAB operon, which encodes heat-labile enterotoxin in enterotoxigenic 
Escherichia coli, by binding to regions downstream of the promoter. Microbiology 2005, 151, 
1199–1208. 
44.  Hamilton, D.L.; Johnson, M.R.; Forsyth, G.W.; Roe, W.E.; Nielsen, N.O. The effect of cholera 
toxin and heat labile and heat stable Escherichia coli enterotoxin on cyclic AMP concentrations 
in small intestinal mucosa of pig and rabbit. Can. J. Comp. Med. 1978, 42, 327–331. 
45.  Bodero, M.D.; Munson, G.P. Cyclic AMP receptor protein-dependent repression of heat-labile 
enterotoxin. Infect. Immun. 2009, 77, 791–798. 
46.  Ferraris, R.P.; Yasharpour, S.; Lloyd, K.C.; Mirzayan, R.; Diamond, J.M. Luminal glucose 
concentrations in the gut under normal conditions. Am. J. Physiol. 1990, 259, G822–G837. 
47.  Spicer, E.K.; Noble, J.A. Escherichia coli heat-labile enterotoxin. Nucleotide sequence of the A 
subunit gene. J. Biol. Chem. 1982, 257, 5716–5721. 
48.  Yamamoto, T.; Tamura, T.; Ryoji, M.; Kaji, A.; Yokota, T.; Takano, T. Sequence analysis of the 
heat-labile enterotoxin subunit B gene originating in human enterotoxigenic Escherichia coli. J. 
Bacteriol. 1982, 152, 506–509. 
49.  Hirst, T.R.; Randall, L.L.; Hardy, S.J. Cellular location of heat-labile enterotoxin in Escherichia 
coli. J. Bacteriol. 1984, 157, 637–642. 
50.  Hofstra, H.; Witholt, B. Heat-labile enterotoxin in Escherichia coli. Kinetics of association of 
subunits into periplasmic holotoxin. J. Biol. Chem. 1985, 260, 16037–16044. 
51.  Chung, W.Y.; Carter, R.; Hardy, T.; Sack, M.; Hirst, T.R.; James, R.F. Inhibition of Escherichia 
coli  heat-labile enterotoxin B subunit pentamer (EtxB5) assembly in vitro using monoclonal 
antibodies. J. Biol. Chem. 2006, 281, 39465–39470. 
52.  Yu, J.; Webb, H.; Hirst, T.R. A homologue of the Escherichia coli DsbA protein involved in 
disulphide bond formation is required for enterotoxin biogenesis in Vibrio cholerae. Mol. 
Microbiol. 1992, 6, 1949–1958. 
53.  Ruddock, L.W.; Webb, H.M.; Ruston, S.P.; Cheesman, C.; Freedman, R.B.; Hirst, T.R. A pH-
dependent conformational change in the B-subunit pentamer  of  Escherichia coli  heat-labile 
enterotoxin: structural basis and possible functional role for a conserved feature of the AB5 toxin 
family. Biochemistry 1996, 35, 16069–16076. 
54.  Streatfield, S.J.; Sandkvist, M.; Sixma, T.K.; Bagdasarian, M.; Hol, W.G.; Hirst, T.R. 
Intermolecular interactions between the A and B subunits of heat-labile enterotoxin from Toxins 2010, 2                         
 
 
1466 
Escherichia coli promote holotoxin assembly and stability in vivo. Proc. Natl. Acad. Sci. USA 
1992, 89, 12140–12144. 
55.  Sixma, T.K.; Pronk, S.E.; Kalk, K.H.; Wartna, E.S.; van Zanten, B.A.; Witholt, B.; Hol, W.G. 
Crystal structure of a cholera toxin-related heat-labile enterotoxin from E. coli. Nature 1991, 351, 
371–377. 
56.  Gankema, H.; Wensink, J.; Guinee, P.A.; Jansen, W.H.; Witholt, B. Some characteristics of the 
outer membrane material released by growing enterotoxigenic Escherichia coli. Infect. Immun. 
1980, 29, 704–713. 
57.  Jacks, T.M.; Wu, B.J.; Braemer, A.C.; Bidlack, D.E. Properties of the enterotoxic component in 
Escherichia coli enteropathogenic for swine. Infect. Immun. 1973, 7, 178–189. 
58.  Neill, R.J.; Ivins, B.E.; Holmes, R.K. Synthesis and secretion of the plasmid-coded heat-labile 
enterotoxin of Escherichia coli in Vibrio cholerae. Science 1983, 221, 289–291. 
59.  Sandkvist, M.; Michel, L.O.;  Hough, L.P.; Morales, V.M.; Bagdasarian, M.; Koomey, M.; 
DiRita, V.J. General secretion pathway (eps) genes required for toxin secretion and outer 
membrane biogenesis in Vibrio cholerae. J. Bacteriol. 1997, 179, 6994–7003. 
60.  Johnson, T.L.; Abendroth, J.; Hol, W.G.; Sandkvist, M. Type II secretion: from structure to 
function. FEMS Microbiol. Lett. 2006, 255, 175–186. 
61.  Tauschek, M.; Gorrell, R.J.; Strugnell, R.A.; Robins-Browne, R.M. Identification of a protein 
secretory pathway for the secretion of heat-labile enterotoxin by an enterotoxigenic strain of 
Escherichia coli. Proc. Natl. Acad. Sci. USA 2002, 99, 7066–7071. 
62.  Horstman, A.L.; Kuehn, M.J. Bacterial surface association of heat-labile enterotoxin through 
lipopolysaccharide after secretion via the general secretory pathway. J. Biol. Chem. 2002, 277, 
32538–32545. 
63.  Yang, J.; Baldi, D.L.; Tauschek, M.; Strugnell, R.A.; Robins-Browne, R.M. Transcriptional 
regulation of the yghJ-pppA-yghG-gspCDEFGHIJKLM cluster, encoding the type II secretion 
pathway in enterotoxigenic Escherichia coli. J. Bacteriol. 2007, 189, 142–150. 
64.  Francetic, O.; Belin, D.; Badaut, C.; Pugsley, A.P. Expression of the endogenous type II secretion 
pathway in Escherichia coli  leads to chitinase secretion. EMBO J.  2000,  19,  
6697–6703. 
65.  Mudrak, B.; Kuehn, M.J. Specificity of the type II secretion systems of enterotoxigenic 
Escherichia coli and Vibrio cholerae for heat-labile enterotoxin and cholera toxin. J. Bacteriol. 
2010, doi:10.1128/JB.01542-09. 
66.  Hirst, T.R.; Sanchez, J.; Kaper, J.B.; Hardy, S.J.; Holmgren, J. Mechanism of toxin secretion by 
Vibrio cholerae investigated in strains harboring plasmids that encode heat-labile enterotoxins of 
Escherichia coli. Proc. Natl. Acad. Sci. USA 1984, 81, 7752–7756. 
67.  Connell, T.D.; Metzger, D.J.; Wang, M.; Jobling, M.G.; Holmes, R.K. Initial studies of the 
structural signal for extracellular transport of cholera toxin and other proteins recognized by 
Vibrio cholerae. Infect. Immun. 1995, 63, 4091–4098. 
68.  Brown, E.A.; Hardwidge, P.R. Biochemical characterization of the enterotoxigenic Escherichia 
coli LeoA protein. Microbiology 2007, 153, 3776–3784. Toxins 2010, 2                         
 
 
1467 
69.  Fleckenstein, J.M.; Lindler, L.E.; Elsinghorst, E.A.; Dale, J.B. Identification of a gene within a 
pathogenicity island of enterotoxigenic Escherichia coli H10407 required for maximal secretion 
of the heat-labile enterotoxin. Infect. Immun. 2000, 68, 2766–2774. 
70.  Turner, S.M.; Chaudhuri, R.R.; Jiang, Z.D.; DuPont, H.; Gyles, C.; Penn, C.W.; Pallen, M.J.; 
Henderson, I.R. Phylogenetic comparisons reveal multiple acquisitions of the toxin genes by 
enterotoxigenic Escherichia coli strains of different evolutionary lineages. J. Clin. Microbiol. 
2006, 44, 4528–4536. 
71.  Horstman, A.L.; Kuehn, M.J. Enterotoxigenic Escherichia coli  secretes active heat-labile 
enterotoxin via outer membrane vesicles. J. Biol. Chem. 2000, 275, 12489–12496. 
72.  Wai, S.N.; Takade, A.; Amako, K. The release of outer membrane vesicles from the strains of 
enterotoxigenic Escherichia coli. Microbiol. Immunol. 1995, 39, 451–456. 
73.  Kuehn, M.J.; Kesty, N.C. Bacterial outer membrane vesicles and the host-pathogen interaction. 
Genes Dev. 2005, 19, 2645–2655. 
74.  Ellis, T.N.; Kuehn, M.J. Virulence and immunomodulatory roles of bacterial outer membrane 
vesicles. Microbiol. Mol. Biol. Rev. 2010, 74, 81–94. 
75.  Moss, J.; Osborne, J.C., Jr.; Fishman, P.H.; Nakaya, S.; Robertson, D.C. Escherichia coli heat-
labile enterotoxin. Ganglioside specificity and ADP-ribosyltransferase activity. J. Biol. Chem. 
1981, 256, 12861–12865. 
76.  Merritt, E.A.; Sixma, T.K.; Kalk, K.H.; van Zanten, B.A.; Hol, W.G. Galactose-binding site in 
Escherichia coli heat-labile enterotoxin (LT) and cholera toxin (CT). Mol. Microbiol. 1994, 13, 
745–753. 
77.  De Wolf, M.J.; Fridkin, M.; Kohn, L.D. Tryptophan residues of cholera toxin and its A and B 
protomers. Intrinsic fluorescence and solute quenching upon interacting with the ganglioside 
GM1, oligo-GM1, or dansylated oligo-GM1. J. Biol. Chem. 1981, 256, 5489–5496. 
78.  Ruddock, L.W.; Coen, J.J.; Cheesman, C.; Freedman, R.B.; Hirst, T.R. Assembly of the B 
subunit pentamer of Escherichia coli heat-labile enterotoxin. Kinetics and molecular basis of 
rate-limiting steps in vitro. J. Biol. Chem. 1996, 271, 19118–19123. 
79.  Merritt, E.A.; Sarfaty, S.; van den Akker, F.; L'Hoir, C.; Martial, J.A.; Hol, W.G. Crystal 
structure of cholera toxin B-pentamer bound to receptor GM1 pentasaccharide. Protein Sci. 1994, 
3, 166–175. 
80.  Wolf, A.A.; Jobling, M.G.; Saslowsky, D.E.; Kern, E.; Drake, K.R.; Kenworthy, A.K.; Holmes, 
R.K.; Lencer, W.I. Attenuated endocytosis and toxicity of a mutant cholera toxin with decreased 
ability to cluster ganglioside GM1 molecules. Infect. Immun. 2008, 76, 1476–1484. 
81.  Holmgren, J.; Fredman, P.; Lindblad, M.; Svennerholm, A.M.; Svennerholm, L. Rabbit intestinal 
glycoprotein receptor for Escherichia coli  heat-labile enterotoxin lacking affinity for cholera 
toxin. Infect. Immun. 1982, 38, 424–433. 
82.  Fan, E.; Merritt, E.A.; Zhang, Z.; Pickens, J.C.; Roach, C.; Ahn, M.; Hol, W.G. Exploration of 
the GM1 receptor-binding site of heat-labile enterotoxin and cholera toxin by phenyl-ring-
containing galactose derivatives. Acta Crystallogr. D Biol. Crystallogr. 2001, 57, 201–212. Toxins 2010, 2                         
 
 
1468 
83.  Minke, W.E.; Roach, C.; Hol, W.G.; Verlinde, C.L. Structure-based exploration of the 
ganglioside GM1 binding sites of Escherichia coli heat-labile enterotoxin and cholera toxin for 
the discovery of receptor antagonists. Biochemistry 1999, 38, 5684–5692. 
84.  Wernick, N.L.B.; Chinnapen, D.J.-F.; Cho, J.A.; Lencer, W.I. Cholera toxin: An intracellular 
journey into the cytosol by way of the endoplasmic reticulum. Toxins 2010, 2, 310–325. 
85.  Connell, T.D. Cholera toxin, LT-I, LT-IIa and LT-IIb: the critical role of ganglioside binding in 
immunomodulation by type I and type II heat-labile enterotoxins. Expert Rev. Vaccines 2007, 6, 
821–834. 
86.  Mudrak, B.; Rodriguez, D.L.; Kuehn, M.J. Residues of heat-labile enterotoxin involved in 
bacterial cell surface binding. J. Bacteriol. 2009, 191, 2917–2925. 
87.  Jansson, L.; Angstrom, J.; Lebens, M.; Imberty, A.; Varrot, A.; Teneberg, S. Carbohydrate 
binding specificities and crystal structure of the cholera toxin-like B-subunit from Citrobacter 
freundii. Biochimie 2010, 92, 482–490. 
88.  MacKenzie, C.R.; Hirama, T.; Lee, K.K.; Altman, E.; Young, N.M. Quantitative analysis of 
bacterial toxin affinity and specificity for glycolipid receptors by surface plasmon resonance. J. 
Biol. Chem. 1997, 272, 5533–5538. 
89.  Teneberg, S.; Hirst, T.R.; Angstrom, J.; Karlsson, K.A. Comparison of the glycolipid-binding 
specificities of cholera toxin and porcine Escherichia coli heat-labile enterotoxin: identification 
of a receptor-active non-ganglioside glycolipid for the heat-labile toxin in infant rabbit small 
intestine. Glycoconj. J. 1994, 11, 533–540. 
90.  Fukuta, S.; Magnani, J.L.; Twiddy, E.M.; Holmes, R.K.; Ginsburg, V. Comparison of the 
carbohydrate-binding specificities of cholera toxin and Escherichia coli heat-labile enterotoxins 
LTh-I, LT-IIa, and LT-IIb. Infect. Immun. 1988, 56, 1748–1753. 
91.  Chatterjee, A.; Chowdhury, R. Bile and unsaturated fatty acids inhibit the binding of cholera 
toxin and Escherichia coli  heat-labile enterotoxin to GM1 receptor. Antimicrob. Agents 
Chemother. 2008, 52, 220–224. 
92.  Lasaro, M.A.; Rodrigues, J.F.; Mathias-Santos, C.;  Guth, B.E.; Balan, A.; Sbrogio-Almeida, 
M.E.; Ferreira, L.C. Genetic diversity of heat-labile toxin expressed by enterotoxigenic 
Escherichia coli strains isolated from humans. J. Bacteriol. 2008, 190, 2400–2410. 
93.  Balanzino, L.E.; Barra, J.L.; Galvan, E.M.; Roth, G.A.; Monferran, C.G. Interaction of cholera 
toxin and Escherichia coli heat-labile enterotoxin with glycoconjugates from rabbit intestinal 
brush border membranes: relationship with ABH blood group determinants. Mol. Cell. Biochem. 
1999, 194, 53–62. 
94.  Barra, J.L.; Monferran, C.G.; Balanzino, L.E.; Cumar, F.A. Escherichia coli  heat-labile 
enterotoxin preferentially interacts with blood group A-active glycolipids from pig intestinal 
mucosa and A- and B-active glycolipids from human red cells compared to H-active glycolipids. 
Mol. Cell. Biochem. 1992, 115, 63–70. 
95.  Galvan, E.M.; Roth, G.A.; Monferran, C.G. Participation of ABH glycoconjugates in the 
secretory response to Escherichia coli heat-labile toxin in rabbit intestine. J. Infect. Dis. 1999, 
180, 419–425. Toxins 2010, 2                         
 
 
1469 
96.  Galvan, E.M.; Diema, C.D.; Roth, G.A.; Monferran, C.G. Ability of blood group A-active 
glycosphingolipids to act as Escherichia coli heat-labile enterotoxin receptors in HT-29 cells. J. 
Infect. Dis. 2004, 189, 1556–1564. 
97.  Galvan, E.M.; Roth, G.A.; Monferran, C.G. Functional interaction of Escherichia coli heat-labile 
enterotoxin with blood group A-active glycoconjugates from differentiated HT29 cells. FEBS J. 
2006, 273, 3444–3453. 
98.  Holmner, A.; Lebens, M.; Teneberg, S.; Angstrom, J.; Okvist, M.; Krengel, U. Novel binding site 
identified in a hybrid between cholera toxin and heat-labile enterotoxin: 1.9 A crystal structure 
reveals the details. Structure 2004, 12, 1655–1667. 
99.  Angstrom, J.; Backstrom, M.; Berntsson, A.; Karlsson, N.; Holmgren, J.; Karlsson, K.A.; Lebens, 
M.; Teneberg, S. Novel carbohydrate binding site recognizing blood group A and B determinants 
in a hybrid of cholera toxin and Escherichia coli heat-labile enterotoxin B-subunits. J. Biol. 
Chem. 2000, 275, 3231–3238. 
100.  Jansson, L.; Angstrom, J.; Lebens, M.; Teneberg, S. No direct binding of the heat-labile 
enterotoxin of Escherichia coli to E. coli lipopolysaccharides. Glycoconj. J. 2009, 27, 171–179. 
101.  Harris, J.B.; Khan, A.I.; LaRocque, R.C.; Dorer, D.J.; Chowdhury, F.; Faruque, A.S.; Sack, D.A.; 
Ryan, E.T.; Qadri, F.; Calderwood, S.B. Blood group, immunity, and risk of infection with 
Vibrio cholerae in an area of endemicity. Infect. Immun. 2005, 73, 7422–7427. 
102.  van Loon, F.P.; Clemens, J.D.; Sack, D.A.; Rao, M.R.; Ahmed, F.; Chowdhury, S.; Harris, J.R.; 
Ali, M.; Chakraborty, J.; Khan, M.R.; et al. ABO blood groups and the risk of diarrhea due to 
enterotoxigenic Escherichia coli. J. Infect. Dis. 1991, 163, 1243–1246. 
103.  Qadri, F.; Saha, A.; Ahmed, T.; Al Tarique, A.; Begum, Y.A.; Svennerholm, A.M. Disease 
burden due to enterotoxigenic Escherichia coli in the first 2 years of life in an urban community 
in Bangladesh. Infect. Immun. 2007, 75, 3961–3968. 
104.  Finne, J.; Breimer, M.E.; Hansson, G.C.; Karlsson, K.A.; Leffler, H.; Vliegenthart, J.F.; van 
Halbeek, H. Novel polyfucosylated N-linked glycopeptides with blood group A, H, X, and Y 
determinants from human small intestinal epithelial cells. J. Biol. Chem. 1989, 264, 5720–5735. 
105.  D'Adamo, P.J.; Kelly, G.S. Metabolic and immunologic consequences of ABH secretor and 
Lewis subtype status. Altern. Med. Rev. 2001, 6, 390–405. 
106.  Raetz, C.R.; Whitfield, C. Lipopolysaccharide endotoxins. Annu. Rev. Biochem.  2002,  71,  
635–700. 
107.  Horstman, A.L.; Bauman, S.J.; Kuehn, M.J. Lipopolysaccharide 3-deoxy-D-manno-octulosonic 
acid (Kdo) core determines bacterial association of secreted toxins. J. Biol. Chem. 2004, 279, 
8070–8075. 
108.  Kesty, N.C.; Mason, K.M.; Reedy, M.; Miller, S.E.; Kuehn, M.J. Enterotoxigenic Escherichia 
coli vesicles target toxin delivery into mammalian cells. EMBO J. 2004, 23, 4538–4549. 
109.  Amor, K.; Heinrichs, D.E.; Frirdich, E.; Ziebell, K.; Johnson, R.P.; Whitfield, C. Distribution of 
core oligosaccharide types in lipopolysaccharides from Escherichia coli. Infect. Immun. 2000, 68, 
1116–1124. 
110.  Cox, A.D.; Brisson, J.R.; Varma, V.; Perry, M.B. Structural analysis of the lipopolysaccharide 
from Vibrio cholerae O139. Carbohydr. Res. 1996, 290, 43–58. Toxins 2010, 2                         
 
 
1470 
111.  Sixma, T.K.; Kalk, K.H.; van Zanten, B.A.; Dauter, Z.; Kingma, J.; Witholt, B.; Hol, W.G. 
Refined structure of Escherichia coli heat-labile enterotoxin, a close relative of cholera toxin. J. 
Mol. Biol. 1993, 230, 890–918. 
© 2010 by the authors; licensee MDPI, Basel, Switzerland. This article is an Open Access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/3.0/). 